v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Mar. 31, 2026
Current assets:    
Cash and cash equivalents $ 1,248,456 $ 1,419,232
Marketable securities 2,593,626 2,872,601
Litigation settlement receivable 771,627 770,235
Other current assets 128,371 105,316
Total current assets 4,742,080 5,167,384
Property and equipment, net 11,320 11,986
Operating lease right-of-use assets 78,886 80,416
Investments measured at fair value 444,622 407,985
Other assets 29,585 40,916
Total assets 5,306,493 5,708,687
Current liabilities:    
Accounts payable 25,084 18,002
Accrued expenses 168,740 205,823
Operating lease liabilities 12,384 11,147
Income tax payable 74,182 45,689
Other current liabilities 3,213 583
Total current liabilities 283,603 281,244
Operating lease liabilities, noncurrent 94,768 96,291
Income tax payable, noncurrent 0 38,670
Other liabilities 6,253 70
Total liabilities 384,624 416,275
Commitments and contingencies (Note 10)
Shareholders’ equity:    
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 722,668,062 and 720,352,386 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively 0 0
Additional paid-in capital 5,130,926 5,024,826
Accumulated deficit (900,354) (501,814)
Accumulated other comprehensive income 701 4,358
Shareholders’ equity attributable to Roivant Sciences Ltd. 4,231,273 4,527,370
Noncontrolling interests 690,596 765,042
Total shareholders’ equity 4,921,869 5,292,412
Total liabilities and shareholders’ equity $ 5,306,493 $ 5,708,687